Your source for technology insights, tutorials, and guides.
Discover NVIDIA's Nemotron 3 Nano Omni, an open omni-modal model unifying vision, audio, and language for up to 9x more efficient AI agents.
Q&A on Akeso's ivonescimab ASCO plenary: what survival data means, comparisons to rivals, implications for Summit, and key points to watch.
Wildfire smoke is increasingly harmful, with data showing rising PM2.5 levels causing more health issues like asthma and heart attacks, especially among vulnerable groups.
Q&A covering AstraZeneca's $400M UK expansion revived after US-UK trade deal, and US Supreme Court hearing on skinny labeling in Amarin v. Hikma case.
Democrats, led by Chuck Schumer, propose sweeping health care affordability measures including drug price negotiation, expanded subsidies, and hospital pricing reforms. Obstacles include partisan gridlock and industry lobbying.
Cigna's exit from ACA individual markets in 2027 explained: reasons, impact on 369K members, and focus on Evernorth, PBM, and employer plans.
Hinge Health expands beyond MSK into migraine with a new FDA-cleared neuromodulation device. Learn how it works, who it's for, and what it means for digital health.
A preclinical obesity drug with five mechanisms shows promise in mice. Also: NIH funding crisis, Novartis reshoring, Alzheimer's setback, and more.
FDA proposes removing semaglutide and tirzepatide from the 503B compounding list, citing no clinical need. This could limit access to cheaper versions of Wegovy, Ozempic, Mounjaro, and Zepbound.
Trump replaces Casey Means with Nicole Saphier as surgeon general nominee, analyzing why, who Saphier is, the MAHA movement's role, reactions, and policy implications.
AI outperforms physicians in diagnostic reasoning tests, but researchers urge caution against misinterpreting simulated results as proof of real-world safety.
Key Q&A from STAT's biotech podcast: hair loss drug trials, AI in clinical trials, and Servier's nonprofit M&A strategy with Day One Biopharmaceuticals.
Q&A about surgeon general nominee Nicole Saphier: her medical background, nuanced views on MAHA topics (vaccines, pregnancy, diet, breast cancer), and balanced approach between innovation and evidence.
Dr. Katherine Szarama becomes acting director of FDA's CBER after Vinay Prasad's controversial exit. Learn about her role, CBER's functions, and impacts on vaccines, gene therapies, and blood supply.
J. Craig Venter, a pioneering and controversial scientist, transformed genetics through the Human Genome Project race, marine genomics, and synthetic biology. He died at 79 from cancer treatment complications.
Judge approves Purdue Pharma's criminal sentence, enabling its dissolution and a massive opioid settlement. A new public-benefit company will replace it.
America's fertility anxiety stems from real economic and social barriers like unaffordable childcare, housing, healthcare, and lack of paid leave, not just cultural worries about families.
Julia Vitarello, whose daughter Mila received a custom drug for her rare mutation, is launching a new biotech to scale individualized therapies after her first venture failed due to regulatory gaps.
FDA found low PFAS levels in half of baby formula samples; experts say supply is safe but suggest steps to reduce exposure.
The psychedelic revolution risks leaving people of color behind due to cost, legal barriers, cultural stigma, and lack of diversity in research and media.